Nomura Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nomura Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-22,500	Closed	-$8.95M	–	1684
2025 Q4	$8.95M	Sell	22,500 -13,000	-37%	-$5.75M	0.01%	566
2025 Q3	$16.2M	Buy	+35,500	New	+$14.5M	0.03%	369
2025 Q2	–	Sell	-9,000	Closed	-$2.43M	–	1422
2025 Q1	$2.43M	Buy	+9,000	New	+$2.31M	﹤0.01%	976
2024 Q4	–	Sell	-1,500	Closed	-$413K	–	2156
2024 Q3	$413K	Sell	1,500 -7,300	-83%	-$1.9M	﹤0.01%	1291
2024 Q2	$2.14M	Buy	+8,800	New	+$1.39M	﹤0.01%	921
2023 Q4	–	Sell	-7,000	Closed	-$1.24M	–	1762
2023 Q3	$1.24M	Buy	+7,000	New	+$1.34M	﹤0.01%	915
2022 Q3	–	Sell	-60,000	Closed	-$8.88M	–	1668
2022 Q2	$8.88M	Buy	+60,000	New	+$8.51M	0.03%	379
2015 Q3	–	Sell	-15,000	Closed	-$1.72M	–	1635
2015 Q2	$1.72M	Buy	+15,000	New	+$1.79M	﹤0.01%	885
2014 Q4	–	Sell	-20,000	Closed	-$1.53M	–	2264
2014 Q3	$1.53M	Hold	20,000	–	–	﹤0.01%	1240
2014 Q2	$1.26M	Buy	+20,000	New	+$1.19M	﹤0.01%	1342

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nomura Holdings's ALNY Position: Q2 2026 in Review

Nomura Holdings reduced its Alnylam Pharmaceuticals (ALNY) stake by 42% in Q2 2026, selling an estimated $1.8M and leaving 8,336 shares worth $2.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1047.

Nomura Holdings first reported a position in ALNY in Q3 2013 and has held it in 23 quarters since. The position peaked at $9.05M in Q2 2015. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Nomura Holdings held 8,336 shares of Alnylam Pharmaceuticals worth $2.51M as of Q2 2026.
Nomura Holdings sold 5,963 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.8M.
Alnylam Pharmaceuticals made up ﹤0.01% of Nomura Holdings's portfolio in Q2 2026, its #1047 holding.
Nomura Holdings first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 23 quarters since.
Nomura Holdings's Alnylam Pharmaceuticals position peaked at $9.05M in Q2 2015.
791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.